Indian Journal of Medical Biochemistry

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Related articles

VOLUME 25 , ISSUE 1 ( January-April, 2021 ) > List of Articles

Original Article

Differential Expression of SLC25A38 Gene in Patients of Acute Lymphoblastic Leukemia

Pritam Prakash, Santosh Kumar, Sanjay Kumar, Shraddha Raj, Poonam Sinha

Keywords : Acute lymphoblastic leukemia, Gene expression, Peripheral blood mononucleotide, Solute carrier 25A38

Citation Information : Prakash P, Kumar S, Kumar S, Raj S, Sinha P. Differential Expression of SLC25A38 Gene in Patients of Acute Lymphoblastic Leukemia. Indian J Med Biochem 2021; 25 (1):5-8.

DOI: 10.5005/jp-journals-10054-0168

License: CC BY-NC 4.0

Published Online: 00-00-0000

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract

SLC25A38 gene produces a protein that belongs to the mitochondrial solute carrier family, SLC25. It is implicated in apoptotic pathways, which regulate intrinsic caspase-dependent apoptosis. The present study evaluates the expression of the SLC25A38 gene in acute lymphoblastic leukemia (ALL) patients. Among 30 leukemia patients, 25 were adult males and 5 were adult females. An average of 5.3-fold high expression of SLC25A38 gene among the ALL patients that was normalized to GAPDH relative to normal healthy volunteer was observed. There was a direct positive correlation between blast cell abundance and level of expression (r = 0.408, p = 0.025). The expression level was found to be associated with the proportion of blast cells in the bone marrow. The present results show that expression of SLC25A38 is a common feature in ALL and may be a novel biomarker for prognosis and diagnosis, as well as a potential therapeutic target for ALL.

PDF Share
  1. Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer 2016;16(8):494. DOI: 10.1038/nrc.2016.63.
  2. Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cellul Signal 2014;26(1):149–161. DOI: 10.1016/j.cellsig.2013.09.021.
  3. Faderl S, O’Brien S, Pui C-H, et al. Adult acute lymphoblastic leukemia: Concepts and strategies. Cancer 2010;116(5):1165–1176. DOI: 10.1002/cncr.24862.
  4. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120(9):1868–1876. DOI: 10.1182/blood-2011-09-377713.
  5. Korfi K, Smith M, Swan J, et al. BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors. Cell Death Dis 2016;7(4):e2177. DOI: 10.1038/cddis.2016.70.
  6. Santiago R, Vairy S, Sinnett D, et al. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother 2017;18(11):1081–1099. DOI: 10.1080/14656566.2017.1340938.
  7. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer 2008;112(2):416–432. DOI: 10.1002/cncr.23169.
  8. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010;28(15):2625–2634. DOI: 10.1200/JCO.2009.27.0421.
  9. Eulàlia G, Jordi R, Josep-Maria R. Acute lymphoblastic leukemia of T progenitors: from biology to clinics. Med Clin 2015;144(5):223–229. DOI: 10.1016/j.medcli.2014.01.029.
  10. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373(16):1541–1552. DOI: 10.1056/NEJMra1400972.
  11. Palmieri F, Monné M. Discoveries, metabolic roles and diseases of mitochondrial carriers: a review. Biochim Biophys Acta 2016;1863(10):2362–2378. DOI: 10.1016/j.bbamcr.2016.03.007.
  12. Zhang Y, Zhang Y, Sun K, et al. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol 2019;11(1):1–13. DOI: 10.1093/jmcb/mjy052.
  13. Guernsey DL, Jiang H, Campagna DR, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 2009;41(6):651–653. DOI: 10.1038/ng.359.
  14. Bergmann AK, Campagna DR, Mcloughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010;54(2):273–278. DOI: 10.1002/pbc.22244.
  15. Kannengiesser C, Sanchez M, Sweeney M, et al. Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematoligica 2011;96(6):808–813. DOI: 10.3324/haematol.2010.039164.
  16. Zhang H, Zhang Y, Chen Y, et al. Appoptosin is a novel pro-apoptotic protein and mediates cell death in neurodegeneration. J Neurosci 2012;32(44):15565–15576. DOI: 10.1523/JNEUROSCI.3668-12.2012.
  17. Hediger MA, Romero MF, Peng JB, et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch 2004;447(5):465–468. DOI: 10.1007/s00424-003-1192-y.
  18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods 2001;25(4):402–408. DOI: 10.1006/meth.2001.1262.
  19. Chen H, Lu Q, Zhang Y, et al. Overexpression of SLC25A38 protein on acute lymphoblastic leukemia cells. Oncol Lett 2014;7(5):1422–1426. DOI: 10.3892/ol.2014.1947.
  20. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol 2000;37(4):381–395. DOI: 10.1016/s0037-1963(00)90018-0.
  21. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1(1):75–87. DOI: 10.1016/s1535-6108(02)00018-1.
  22. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005;106(1):274–286. DOI: 10.1182/blood-2004-10-3900.
  23. Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003;102(1):262–268. DOI: 10.1182/blood-2002-10-3221.
  24. Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. J Hematol Oncol 2010;3(1):37. DOI: 10.1186/1756-8722-3-37.
  25. Fernando TR, Rodriguez-Malave NI, Rao DS. MicroRNAs in B cell development and malignancy. J Hematol Oncol 2012;5(1):7. DOI: 10.1186/1756-8722-5-7.
  26. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129–138. DOI: 10.1038/nrd2742.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.